IC
GALT icon

Ikarian Capital’s Galectin Therapeutics GALT Stock Holding History

Ikarian Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,200,000
Closed -$1.55M – 190
2024
Q4 		$1.55M Buy
1,200,000
+700,000
+140% +$1.68M 0.21% 91
2024
Q3 		$1.38M Buy
+500,000
New +$1.23M 0.19% 85

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Ikarian Capital's GALT Position: Q1 2025 in Review

Ikarian Capital sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 100 shares — an estimated $129 sold.

Ikarian Capital first reported a position in GALT in Q4 2024 and held it in 1 quarter. The position peaked at $129 in Q4 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Ikarian Capital reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 100 Galectin Therapeutics shares in Q1 2025, an estimated $129.
  • Ikarian Capital first reported a position in Galectin Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ikarian Capital's Galectin Therapeutics position peaked at $129 in Q4 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.